SRPT new CEO Michael Severino, on his first earnings call, notes September will be the 10-year anniversary of the Exondys approval. One of t
SRPT new CEO Michael Severino, on his first earnings call, notes September will be the 10-year anniversary of the Exondys approval. One of the first questions to him from an analyst: Will you consider separating the DMD business from the sRNA research programs? Adam F X post